Amogha Tadimety, PhD

Why follow Amogha

Amogha Tadimety is Co-founder and co-CEO at Nanopath. Nanopath announced a $25 million Series B financing package on November 10, 2026, including $2 million in non-dilutive grants. Norwest and SV Health Investors' MedTech Convergence Fund co-led, with Labcorp Venture Fund participating. The financing supports manufacturing and initiation of an FDA 510(k) clinical study for a 15-minute vaginitis assay. The assay is under development and has not been FDA cleared or approved. Alison Burklund, PhD and Amogha Tadimety, PhD are co-founders and co-CEOs.